Emma Walmsley

Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work is starting to pay off. Much credit goes to Arexvy, GSK’s first-on-the-market RSV vaccine that was a triumph for GSK after the company failed to develop a COVID jab. Arexvy generated £1.2 billion ($1.6 billion) in sales in its first year after launching in the third quarter of 2023. Sales of Shingrix, its shingles vaccine, are also booming. GSK boosted Walmsley’s compensation 51% in 2023, owing to the company’s strong sales. GSK recorded £30.3 billion ($40.5 billion) in turnover in 2023, up 3.4% from the previous year. Outside of GSK, Walmsley is an independent director at Microsoft.